Navigation Links
VerifyNow System

ProductsVerifyNow System
Company Accumetrics
Item VerifyNow System
Features Each single-use disposable assay device, such as the VerifyNow IIb/IIIa or VerifyNow Aspirin Assay, contains all needed reagents to provide analytical results for a specific assay. Assay devices are individually pouched and may be used until the expiration date printed on each kit box and foil pouch.

The assay device consists of the following components:

  • Finger Grip: Each assay device has a handle with which the user can insert or remove the assay device from the assay device port.
  • Staging Well: The blood sample is held in this area for temperature stabilization prior to analysis.
  • Assay Device Spot Code: Each assay device is labeled with a unique spot code. Upon insertion of the assay device into the assay device port, the instrument automatically scans the spot code and determines which assay is being performed, records the lot number, and verifies that the assay device has not expired.
  • Sample Well: The sample well is the area of the assay device where the blood collection tube is inserted. The well contains a Blood Collection Tube Spike for sampling directly from a closed blood collection tube. A protective sheath is removed from the assay device spike before use.
  • Humidity Indicator: Each assay device has a humidity sensor to determine whether the assay device has been exposed to excess humidity.
  • Mixing Chamber/Detection Wells: The wells contain all necessary reagents for the specific assays.
Description The Company's first commercial product is the VerifyNow System, a point-of-care, bedside instrument with single-use, disposable assay devices . The advantages of the VerifyNow System over previous products are direct use of a vacuum-type blood collection tube (whole blood sample) and a result in minutes. VerifyNow IIb/IIIa, the first assay developed for use on the system is to assess GP IIb/IIIa platelet inhibition in response to abciximab or eptifibatide. VerifyNow Aspirin, the second assay developed for use on the system is to aid in the detection of platelet dysfunction due to aspirin ingestion.

The GP IIb/IIIa inhibitor class of intravenous antiplatelet agents, has demonstrated benefit in treating patients undergoing coronary interventions (e.g. PTCA and stent placement) and acute coronary syndromes. Currently available drugs in this class include ReoPro (Centocor), Integrilin (Millenium Pharmaceuticals) and Aggrastat(Merck & Co.). Accumetrics estimates that over 2.5 million patients annually are candidates for intravenous antiplatelet therapy. Data from clinical trials suggest that both the safety and efficacy of these agents are dependent on achieving a specific level of receptor blockade. Since there are individual variations in the response to these agents, Accumetrics' first product is targeted to address this unmet medical need.

Aspirin, the most commonly used antithrombotic medication in the world, prevents heart attack, stroke, and other vascular events by causing platelet dysfunction, so that platelets will not aggregate. Over 20 million people in the U.S. alone take aspirin daily to prevent platelets from clotting. Clinical data shows that not all patients receive the full benefits of aspirin, therefore it is important to ensure that patients are receiving the expected anti-platelet benefits. Accumetrics second product is designed to address this important medical need.

Info Accumetrics
Customer Service: (800) 643-1640

Related medicine products :

1. VerifyNow Aspirin Assay
2. VerifyNow IIb/IIIa Assay
3. VerifyNow Clopidogrel Assay
4. VerifyNow (Ultegra) System
5. Silicone Oil Cannula System - 20 Gauge
6. Silicone Oil Cannula System - 19 Gauge
7. SuperVu Galilean System
8. KOWA nonmyd 7 / VK-2 Digital Imaging System
9. KOWA nonmyd a-D / VK-2 Digital Imaging System
10. Refraction System RT-2100
11. Odyssey Phacoemulsification System
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products:
(Date:12/24/2014)... FL (PRWEB) December 24, 2014 There’s a ... days. With the Republican Party now in control of the ... again for the Affordable Care Act. A lawsuit has been ... delays of certain provisions in the ACA have resulted in ... Also, a Supreme Court hearing will take place to weigh ...
(Date:12/24/2014)... St. Louis, MO (PRWEB) December 24, 2014 ... Onder Law Firm announce an update to their website, ... information explains the difference between talcum powder class action ... provide weekly talcum powder and ovarian cancer updates at ... , “Talcum powder lawsuits for ovarian cancer claims are ...
(Date:12/24/2014)... Kathleen Doheny HealthDay Reporter ... steady diet of fast food might hurt your child in ... ate fast food in fifth grade lagged behind by eighth ... more than 8,500 U.S. students. "The largest effects were ... food," said study leader Kelly Purtell, assistant professor of human ...
(Date:12/24/2014)... Dec. 23, 2014 (HealthDay News) -- Though most patients ... medication and therapy, between 10 percent to 20 percent ... to standard care, experts say. However, patients with ... form of a type of brain surgery that disables ... The challenge: to distinguish between patients most likely to ...
(Date:12/22/2014)... York, NY (PRWEB) December 22, 2014 ... noticeable toll and can present in the form of ... folds with the start of the marionette line or ... topical treatments and diligent skincare, but as the deep ... and Restylane are all synthetic fillers that can be ...
Breaking Medicine News(10 mins):Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4Health News:Can Fast Food Hinder Learning in Kids? 2Health News:Scans May Spot People Who'll Benefit From Surgery for OCD 2Health News:Sam Rizk, MD, FACS, Introduces Rapid Recovery Facelift 2
... Continued year over year growth driven by Loestrin 24 and Taclonex; ... updates full year 2007 financial guidance, ... ) today announced its results for the quarter ended,September 30, 2007. ... increase of 16.3%, over the prior year quarter. The,primary drivers of ...
... announced today that the U.S. Food and Drug ... adjunct to diet to slow,the progression of atherosclerosis ... CRESTOR an important differentiator from,competitors in the cholesterol-lowering ... share what we,ve learned in clinical,trials -- that ...
... EXTON, Pa. and SAN DIEGO, Nov. 9 ,RS&A, ... of oncology equipment sales and service, announced today ... Radiology Oncology Systems, Inc.,(ROS), an oncology and diagnostic ... a US provider of oncology equipment service,and distributor ...
... 8 State,Compensation Insurance Fund is presenting a ... Fund,s Employer Education Series, featuring its own,innovative and ... seminar entitled "Watch Your Back",introduces an educational and ... the very people they are trying to protect ...
... following release is,being issued by the Department of ... is the largest federal provider of direct assistance ... and case,management, employment, rehabilitation, transitional residential care,therapeutic work ... has been a 22 percent reduction in the ...
... Warns of Critical and Fatal Implications of ... the Diagnosis of Carbon Monoxide Poisoning, IRVINE, Calif., ... Read-Through Motion and Low Perfusion pulse,oximetry, today announced the ... all its members advocating carbon monoxide,screenings for patients presenting ...
Cached Medicine News:Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 2Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 3Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 4Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 5Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 6Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 7Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 8Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 9Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 10Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 11Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 12Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 13Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 14Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 15Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 16Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 17Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 18Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 19Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 20Health News:Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007 21Health News:CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol 2Health News:CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol 3Health News:CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol 4Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 2Health News:RS&A, Inc. Announces It Has Joined Radiology Oncology Systems, Inc. (ROS) and Acceletronics, Inc. in a Strategic Alliance to Better Serve Its Customers in the Southeastern US 3Health News:Free Seminar Features State Fund's Back Connection(TM), November 14, in Chico 2Health News:Free Seminar Features State Fund's Back Connection(TM), November 14, in Chico 3Health News:Homeless Vets - VA Sets the Record Straight 2Health News:National Association of EMS Educators (NAEMSE) Recommends Screening for Carbon Monoxide Poisoning 2Health News:National Association of EMS Educators (NAEMSE) Recommends Screening for Carbon Monoxide Poisoning 3
(Date:12/22/2014)... 22, 2014  Eiger BioPharmaceuticals Incorporated announced the ... lonafarnib in patients with chronic hepatitis delta virus ... National Institutes of Health (NIH) Clinical Center in ... randomized, placebo-controlled, dose ascending study evaluated two doses ... mg twice daily for 28 days.  "This proof-of-concept ...
(Date:12/22/2014)... TWi Biotechnology, Inc., today announced that ... TWi Biotechnology,s lead drug candidate, from The State ... for patent application numbered 201180018154.8.  This patent ... metabolite for treatment of type II diabetes.  The ... AC-201 for type II diabetes, and provides a ...
(Date:12/19/2014)... 2014  Newport Corporation (NASDAQ: NEWP ... joined the company,s Board of Directors.  Dr. Kadia ... director of Evans Analytical Group, a leading global ... services to companies in a wide range of ... Analytical Group, Dr. Kadia spent nine years with ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2